Sign In
Buy CTLT
$63.49
+0 (+0%)
At Close: Mar 14, 2025
Catalent (CTLT) Up 0.4% Since Last Earnings Report: Can It Continue?
12:49pm, Thursday, 02'nd Jun 2022
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?
Catalent, Inc. to Present at June Investor Conferences
08:26am, Friday, 27'th May 2022
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments ac
Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
12:48pm, Monday, 23'rd May 2022
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
Catalent's (CTLT) Latest Facility Expansion to Boost Capacity
12:48pm, Monday, 23'rd May 2022
Catalent's (CTLT) latest site expansion is expected to significantly boost its business.
Catalent's (CTLT) New Launch to Enhance Gene Therapy Development
02:18pm, Thursday, 19'th May 2022
Catalent's (CTLT) latest launch is expected to provide a reliable, reproducible and scalable path to clinic to its customers.
Buy Catalent After Undeserved Selloff
02:43pm, Monday, 16'th May 2022
Catalent is the right combination for the 2022 environment with growth and stability - growing earnings and a diversified revenue base. All product categories have shown strength with strong potential
Catalent Shares Jump As Investors Cheer Revised, Better Than Expected FY22 Outlook
02:21pm, Tuesday, 03'rd May 2022
Catalent Inc (NYSE: CTLT) reported Q3 FY22 sales of $1.27 billion, +21% Y/Y as reported, or 23% in constant currency, edging out analysts' average expectation of $1.22 billion. Adjusted EPS of $1.04
Catalent, Inc. (CTLT) CEO John Chiminski on Q3 2022 Results - Earnings Call Transcript
01:02pm, Tuesday, 03'rd May 2022
Catalent, Inc. (NYSE:CTLT ) Q3 2022 Earnings Conference Call May 3, 2022 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations John Chiminski - Chair and Chief Executive Off
Catalent (CTLT) Q3 Earnings Beat Estimates, FY22 View Up
12:02pm, Tuesday, 03'rd May 2022
Catalent's (CTLT) robust performance across most of its segments drives its third-quarter fiscal 2022 top line.
Catalent (CTLT) Tops Q3 Earnings and Revenue Estimates
09:47am, Tuesday, 03'rd May 2022
Catalent (CTLT) delivered earnings and revenue surprises of 10.64% and 4.38%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Catalent (CTLT) Ahead of Earnings?
09:47am, Monday, 02'nd May 2022
Catalent (CTLT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Catalent (CTLT) is Poised to Beat Earnings Estimates Again
01:32pm, Monday, 25'th Apr 2022
Catalent (CTLT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Catalent's (CTLT) Latest Manufacturing Suites to Boost Capacity
11:17am, Monday, 18'th Apr 2022
Catalent's (CTLT) latest site expansion is expected to significantly boost its business.
Catalent, Inc. Announces Third Quarter Fiscal Year 2022 Earnings Conference Webcast
09:00am, Friday, 15'th Apr 2022
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene t
Catalent's (CTLT) Latest Buyout to Expand Its Global Footprint
11:18am, Thursday, 07'th Apr 2022
Catalent's (CTLT) latest acquisition is likely to significantly enhance its global Biologics business.
